ENDPOINTS NEWS49m
Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er
After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro ...